Yazawa S, Akamatsu S, Tachikawa T, Naito H, Nakamura J, Asao T, Nagamachi Y, Nakajima T, Shin S, Chia D
Department of Legal Medicine, Gunma University School of Medicine, Maebashi.
Jpn J Cancer Res. 1993 Jun;84(6):641-8. doi: 10.1111/j.1349-7006.1993.tb02024.x.
A novel monoclonal antibody, YB-2 was obtained after immunization of mice with fucosylated antigens isolated from human saliva. The antibody was demonstrated to react with Y (Fuc alpha 1-->2Gal-beta 1-->4[Fuc alpha 1-->3]GlcNAc beta),Leb (Fuc alpha 1-->2Gal beta 1-->3[Fuc alpha 1-->4]GlcNAc beta) and H type 2 (Fuc alpha 1-->2Gal-beta 1-->4GlcNAc beta) antigens, but not with H type 1 (Fuc alpha 1-->2Gal beta 1-->3GlcNAc beta), Lea (Gal beta 1-->3[Fuc alpha 1-->4]GlcNAc beta), X (Gal beta 1-->4[Fuc alpha 1-->3]GlcNAc beta) or with non-fucosylated antigens. Inhibition assays of YB-2 antibody with such reactive antigens showed that YB-2 antibody preferentially reacted with Y antigen. Formalin-fixed and paraffin-embedded sections prepared from normal and malignant colorectal tissues were examined immunohistochemically with YB-2. The positive rates of staining with YB-2 antibody were 88.6% in malignant and 12.0% in normal tissues. The expression of fucosylated antigens detected by YB-2 antibody seemed to be correlated with survival among patients with primary colorectal cancer. Therefore, YB-2 antibody could be useful as an immunochemical tool for diagnosis and evaluation of the prognosis of colorectal cancer.
用从人唾液中分离出的岩藻糖基化抗原免疫小鼠后,获得了一种新型单克隆抗体YB - 2。已证明该抗体可与Y(岩藻糖α1→2半乳糖-β1→4[岩藻糖α1→3]N - 乙酰葡糖胺β)、Leb(岩藻糖α1→2半乳糖β1→3[岩藻糖α1→4]N - 乙酰葡糖胺β)和H2型(岩藻糖α1→2半乳糖-β1→4N - 乙酰葡糖胺β)抗原发生反应,但不与H1型(岩藻糖α1→2半乳糖β1→3N - 乙酰葡糖胺β)、Lea(半乳糖β1→3[岩藻糖α1→4]N - 乙酰葡糖胺β)、X(半乳糖β1→4[岩藻糖α1→3]N - 乙酰葡糖胺β)或非岩藻糖基化抗原发生反应。用此类反应性抗原对YB - 2抗体进行抑制试验表明,YB - 2抗体优先与Y抗原发生反应。用YB - 2对从正常和恶性结直肠组织制备的福尔马林固定石蜡包埋切片进行免疫组织化学检查。YB - 2抗体染色的阳性率在恶性组织中为88.6%,在正常组织中为12.0%。YB - 2抗体检测到的岩藻糖基化抗原的表达似乎与原发性结直肠癌患者的生存率相关。因此,YB - 2抗体可作为一种免疫化学工具用于结直肠癌的诊断和预后评估。